The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.